Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.
On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…
All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on interventions such as self-isolation, contact tracing, and antiviral treatment.
People at risk of tuberculosis (TB) have a right to TB screening and diagnostic testing in accordance with the standard of care recommended by the World Health Organization (WHO). Yet, many countries with high burdens of TB have limited uptake…
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.
This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.